CD274 and non-small cell lung carcinoma: In particular, a landmark phase III study in 2016, KEYNOTE-024, showed that non-small-cell lung cancer (NSCLC) patients expressing PD-L1 on over 50% of tumour cells experienced a longer progression-free survival and overall survival after treatment with pembrolizumab compared to platinum-based chemotherapy [18].